Withdrawn
PHASE1
INTERVENTIONAL
NCT05456854
Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an hyperglycemic clamp
Detailed Description
Assignment: Each study subject will serve as their own control. The order of the visits will be randomized. Delivery of Interventions: Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. During the inpatient study, the subjects will Undergo a 16-hour kisspeptin infusion Undergo a hyperglycemic clamp
Interventions
Name:
Hyperglycemic Clamp
Type:
DIAGNOSTIC_TEST
Description:
Administration of a hyperglycemic clamp
Name:
Kisspeptin-10
Type:
DRUG
Description:
Administration of kisspeptin-10 \* 16 hr
Name:
Placebo
Type:
DRUG
Description:
Administration of placebo \*16 hr
Primary Outcomes
Measure:
First Phase Insulin Secretion
TimeFrame:
10 minutes
Description:
Average Change in First Phase Insulin Secretion Between Kisspeptin and Placebo Arms
Measure:
Second Phase Insulin Secretion
TimeFrame:
2 hours
Description:
Average Change in Second Phase Insulin Secretion Between Kisspeptin and Placebo Arms
Trial Information
NCT ID
NCT05456854
Status
Withdrawn
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Massachusetts General Hospital
Last Updated
December 15, 2025